Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
141.50    0.00 (0.00%)
Bid:
140.00
Ask:
143.00
Spread: 3.00 (2.143%)
Market Cap: £119.75m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Expanded lab network and data capabilities

27 Feb 2024 07:00

RNS Number : 5258E
Diaceutics PLC
27 February 2024
 

Diaceutics grows its lab network and data capabilities in Europe

 

New data will deliver enhanced insights to Diaceutics' customers and drive new sales opportunities across multiple geographies

 

Belfast and London, 27 February 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce it has expanded its data supply network which will significantly increase the number of labs through which Diaceutics is sourcing data in Europe and will broaden the Company's European data coverage. This data will accelerate the rollout of the DxRx Signal product in key EU markets of Germany, France, Italy, Spain and the United Kingdom (DxRx Signal has only previously been offered by Diaceutics in the US market).

The increased data is now available to Diaceutics customers enabling them to find more patients eligible for their new and innovative therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "This data will further endorse our position as a leading provider of data to biotech and pharma companies as they commercialize their products, find and deliver therapies to patients across multiple geographies."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer. 

 

Enquiries: 

Diaceutics PLC?

 Tel: +44 (0)28 9040 6500 

Ryan Keeling, Chief Executive Officer 

Nick Roberts, Chief Financial Officer

Jordan Clark, Chief Data Officer

investorrelations@diaceutics.com 

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 

Nick Harland 

Kate Hanshaw 

Alma Strategic Communications 

Tel: +44 (0)20 3405 0205 

Caroline Forde 

diaceutics@almastrategic.com 

Kinvara Verdon 

 

About Diaceutics 

At Diaceutics we believe that?every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDXGDDDBDDGSL
Date   Source Headline
17th Dec 202410:46 amRNSHolding(s) in Company
17th Dec 20247:00 amRNSDiaceutics Wins New $5.1m Contract
10th Dec 20243:14 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSAwarded UK Research Institute Grant Funding of £1m
3rd Dec 20242:24 pmRNSTotal Voting Rights
28th Nov 20247:00 amRNSExpansion of US Commercial Activities
5th Nov 20247:00 amRNSCapital Markets Webinar
4th Nov 20247:00 amRNSHolding(s) in Company
30th Oct 20242:58 pmRNSPDMR Shareholding/Share Incentive Plan
29th Oct 202410:27 amRNSBoard Change Update
25th Oct 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
24th Oct 202412:53 pmRNSCancellation of Share Premium Account
15th Oct 20247:00 amRNS-RDiaceutics Announces Key Leadership Appointment
7th Oct 20241:19 pmRNSHolding(s) in Company
7th Oct 20247:00 amRNSBlock Listing Return
2nd Oct 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Oct 20247:00 amRNSBoard Changes
17th Sep 20247:00 amRNSH1 2024 Results - Continued Performance & Growth
9th Sep 20247:00 amRNSNotice of Results & Presentations
2nd Sep 20247:00 amRNSAppointment of Nominated Adviser and Broker
30th Aug 20243:45 pmRNSPDMR Shareholding/Share Incentive Plan
27th Aug 20247:00 amRNSDiaceutics Launches Enhanced Rare-Disease Offering
19th Aug 20247:00 amRNSEnterprise Partnership and Launch of PMx
5th Aug 20247:00 amRNSPresenting at Canaccord Genuity Growth Conference
29th Jul 20246:09 pmRNSPDMR Shareholding/SIP and TVR
29th Jul 20247:00 amRNSIssue of Share Options/PDMR Shareholdings
23rd Jul 20247:05 amRNSBoard Changes
23rd Jul 20247:00 amRNSRevenue growth of 24% in H1 with 55% now recurring
11th Jul 20247:00 amRNSSenior Management Appointments
1st Jul 20247:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
24th Jun 20241:15 pmRNSResult of AGM
6th Jun 20247:00 amRNSDiaceutics - Capital Markets Event
29th May 20248:00 amRNSNotice of AGM and Posting of Annual Report
28th May 20247:00 amRNSData to be Presented at 2024 ASCO Annual Meeting
24th May 20243:01 pmRNSPDMR Shareholding/SIP and Total Voting Rights
23rd May 20247:00 amRNSDirector / PDMR Shareholding
21st May 20247:00 amRNSRevenue growth of 22% & order book growth of 57%
16th May 20247:00 amRNSTwo New Enterprise-Wide Engagements
14th May 20247:00 amRNSDiaceutics - Capital Markets Event
1st May 20247:00 amRNSNotice of Results & Presentations
30th Apr 20247:00 amRNSPDMR Shareholding/SIP and TVR
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR
27th Feb 20247:00 amRNSExpanded lab network and data capabilities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.